Adamis Submits Covid Drug to FDA

 Shares of Adamis Pharmaceuticals  (ADMP)  skyrocketed Wednesday after the biopharmaceutical company announced a request to the Food and Drug Administration for investigational use of its Covid-19 treatment drug Tempol.

The request followed a meeting with the FDA in which it gave specific recommendations on chemistry, manufacturing and controls and clinical aspects to be included in the drug, Adamis said. It plans to seek government and/or non-government funding to study the treatment and prevention of Covid-19, the disease caused by the coronavirus, with Tempol.

https://www.thestreet.com/investing/adamis-admp-covid-drug-fda